MedCity brings together the vibrant life sciences ecosystem of England’s greater south east, including the world-leading university cities of London, Oxford and Cambridge.
This region boasts five out of the UK’s six Academic Health Science Centres and four universities regularly placed in the global top 10.
It is home to leading medical research institutes including the Wellcome Trust, the Medical Research Council, Cancer Research UK, and the national Cell Therapy Catapult, focusing on stem cell research and industrialisation.
New investment in the science base of the region includes:
The Francis Crick Institute: The Crick provides space for 1,500 scientists in 120 research groups, with a focus on finding new ways to treat, diagnose and prevent a range of illnesses.
White City Campus: Imperial College London’s major new 25 acre campus, co-locating researchers, businesses and educational partners to create value from ideas; includes Michael Uren Biomedical Engineering Research Hub and the I-HUB.
The London Cancer Hub: This partnership between The Institute of Cancer Research, London, and the London Borough of Sutton aims for the London Cancer Hub to be a global centre for cancer innovation. When complete, the development will offer more than 280,000 square metres of integrated life-science buildings including facilities for cancer research, diagnosis, treatment, education and commercial collaboration.
UCL East: Construction to commence in 2019 on the site of Queen Elizabeth Olympic Park, creating a cross-disciplinary centre for entrepreneurship and innovation; to include UCL Innovation, a series of incubators focused on commercialisation of biological devices, wearable sensors for health monitoring, and technologies to promote well-being.
Queen Mary University of London Life Sciences Institute: a research, education and public engagement cluster across QMUL’s east London campuses that will work with the NHS and industry with a particular focus on healthcare in the post-genomic era.
Cell Therapy Catapult manufacturing centre: £60m centre at the Stevenage Bioscience Catalyst opened in April 2018, and will provide the global Advanced Therapeutics industry with the infrastructure to develop manufacturing capability and systems for large-scale cell and gene therapy clinical studies, and accelerate commercialisation.
The Cube at Londoneast-uk: A post-incubator science facility in Dagenham for small and growing companies, with access to specialist laboratories and technical support.
The region offers an ideal base for clinical trials, with a highly diverse patient population of over eight million, served by the National Health Service – a large single healthcare system that can facilitate access to extensive data.
The greater south east is outward-facing and has a global reach, with extensive transport links to the rest of the UK, Europe, the USA and Asia.